Neos Therapeutics Inc. (NASDAQ:NEOS) saw unusually-high trading volume on Tuesday . Approximately 120,913 shares were traded during trading, an increase of 19% from the previous session’s volume of 101,301 shares.The stock last traded at $7.16 and had previously closed at $7.08.

NEOS has been the subject of several recent analyst reports. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. BMO Capital Markets started coverage on shares of Neos Therapeutics in a research note on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price target for the company. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. Finally, Royal Bank Of Canada decreased their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research note on Tuesday, May 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Neos Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.75.

The firm’s market capitalization is $117.79 million. The company has a 50-day moving average price of $8.46 and a 200 day moving average price of $9.46.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. The business had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.48 million. On average, analysts forecast that Neos Therapeutics Inc. will post ($5.38) EPS for the current fiscal year.

In other Neos Therapeutics news, insider Juergen Martens acquired 10,000 shares of the business’s stock in a transaction on Monday, June 13th. The stock was bought at an average price of $9.90 per share, for a total transaction of $99,000.00. Following the acquisition, the insider now owns 10,000 shares in the company, valued at $99,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP raised its position in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.